The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial
Abstract
Purpose: To determine the response rate, time to disease progression, survival duration and rate, and toxicity with the combination of cetuximab and gemcitabine in patients with epidermal growth factor receptor (EGFR)-expressing advanced pancreatic cancer. Patients and Methods: Patients with measurable locally advanced or metastatic pancreatic cancer who had never received chemotherapy for their advanced disease and had immunohistochemical evidence of EGFR expression were eligible for the multicenter phase II trial. Patients were treated with cetuximab at an initial dose of 400 mg/m 2, followed by 250 mg/m 2 weekly for 7 weeks. Gemcitabine was administered at 1,000 mg/m 2 for 7 weeks, followed by 1 week of rest. In subsequent cycles, cetuximab was administered weekly, and gemcitabine was administered weekly for 3 weeks every 4 weeks. Results: Sixty-one patients were screened for EGFR expression, 58 patients (95%) had at least 1+ staining, and 41 were enrolled onto the trial. Five patients (12.2%) achieved a partial response, and 26 (63.4%) had stable disease. The median time to disease progression was 3.8 months, and the median overall survival duration was 7.1 months. One-year progression-free survival and overall survival rates were 12% and 31.7%, respectively. The most frequently reported grade 3 or 4 adverse events were neutropenia (39.0%), asthenia (22.0%), abdominal pain (22.0%), and thrombocytopenia (17.1%). Conclusion: Cetuximab in combination with gemcitabine showed promising activity against advanced pancreatic cancer. Further clinical investigation is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435
Jemal, A., Thomas, A., Murray, T., & Thun, M. (2002) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.52.1.23 · Cited by 2,917
WHO Handbook for Reporting Results of Cancer Treatment
Palmer, M. K. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.83 · Cited by 2,198
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Goldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 910
Transforming Growth Factor-α: a More Potent Angiogenic Mediator than Epidermal Growth Factor
Schreiber, A. B., Winkler, M. E., & Derynck, R. (1986) · Science · doi:10.1126/science.2422759 · Cited by 838
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Cohen, E. E. W., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D., & Vokes, E. E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.051 · Cited by 610
Herbst, R. S., Maddox, A.-M., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.038 · Cited by 572
The EGFR as a target for anticancer therapy—focus on cetuximab
Baselga, J. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00233-7 · Cited by 563
Goldman, C. K., Kim, J., Wong, W. L., King, V, Brock, T., & Gillespie, G. Y. (1993) · Molecular Biology of the Cell · doi:10.1091/mbc.4.1.121 · Cited by 531
Yamanaka, Y., Frieß, H., Kobrin, M. S., Büchler, M. W., Hg, B., & Korc, M. (1993) · PubMed · Cited by 461
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.
Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J. M., Polikoff, J., & SATO, G. H. (1983) · PubMed · Cited by 458
Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., & Mendelsohn, J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42857-2 · Cited by 455
Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., & Mendelsohn, J. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)50005-1 · Cited by 446
Bruns, C. J., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R. Z., McConkey, D. J., Evans, D. B., Abbruzzese, J. L., Hicklin, D. J., & Radinsky, R. (2000) · PubMed · Cited by 422
Self-citationBusam, K. J., Capodieci, P., Motzer, R., Kiehn, T., Phelan, D., & Halpern, A. C. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04226.x · Cited by 419
Targeting the epidermal growth factor receptor for cancer therapy.
Mendelsohn, J. M. (2002) · PubMed · Cited by 414
Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., & Mendelsohn, J. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.16.1327 · Cited by 411
Wu, X., Fan, Z., Masui, H., Rosen, N., & Mendelsohn, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117871 · Cited by 381
Prewett, M. C., Hooper, A. T., Bassi, R., Ellis, L. M., Waksal, H. W., & Hicklin, D. J. (2002) · PubMed · Cited by 352
Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.
Mendelsohn, J. M. (1997) · PubMed · Cited by 344
The epidermal growth factor receptor in human pancreatic cancer
Lemoine, N. R., Hughes, C. M., Barton, C. M., Poulsom, R., Jeffery, R. E., Klöppel, G., Hall, P. A., & Gullick, W. J. (1992) · The Journal of Pathology · doi:10.1002/path.1711660103 · Cited by 205
Chemoprevention of Breast Cancer: A Model for Change
Jordan, V. C., & Morrow, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.1.1 · Cited by 197
A multispecialty approach to the diagnosis and management of pancreatic cancer
Hawes, R. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00758-3 · Cited by 166
Overholser, J. P., Prewett, M. C., Hooper, A. T., Waksal, H. W., & Hicklin, D. J. (2000) · Cancer · doi:10.1002/1097-0142(20000701)89:1<74::aid-cncr11>3.0.co;2-k · Cited by 165
Epidermal growth factor receptor-targeted therapy for pancreatic cancer
XIONG, H., & Abbruzzese, J. L. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70088-2 · Cited by 125
Self-citationBuchsbaum, D. J., Bonner, J. A., Grizzle, W. E., Stackhouse, M. A., Carpenter, M., Hicklin, D. J., Böhlen, P., & Raisch, K. P. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03788-4 · Cited by 113
Karashima, T., Sweeney, P., Slaton, J. W., Kim, S. J., Kedar, D. J., Izawa, J. I., Fan, Z., Pettaway, C. A., Hicklin, D. J., Shuin, T., et al. (2002) · PubMed · Cited by 96
Sclabas, G. M., Fujioka, S., Schmidt, C., Fan, Z., Evans, D. B., & Chiao, P. J. (2003) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(02)00088-4 · Cited by 56
Liu, B., & Fan, Z. (2001) · Oncogene · doi:10.1038/sj.onc.1204490 · Cited by 41
Current Approaches and Future Strategies for Pancreatic Carcinoma
Wolff, R. A., Chiao, P. J., Lenzi, R., Pisters, P. W. T., Lee, J. E., Janjan, N. A., Crane, C. H., Evans, D. B., & Abbruzzese, J. L. (2000) · Investigational New Drugs · doi:10.1023/a:1006383831045 · Cited by 38
Self-citation
Cited by
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Self-citationEGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 950
Advanced pancreatic carcinoma: current treatment and future challenges
Stathis, A., & Moore, M. J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.236 · Cited by 790
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 632
Self-citation
Metadata
- Authors
- Xiong, H. Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R. A., Deutsch, J., Needle, M., & Abbruzzese, J. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-01
- Volume
- 22
- Issue
- 13
- Pages
- 2610-2616
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2054870962
- Cited by
- 479
- References
- 34
- FWCI
- 24.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.